The global checkpoint inhibitor-resistant cancer industry size is projected to be valued US$ 38.69 billion in 2023. Expectedly, the global market for Checkpoint Inhibitor Refractory Cancer will rise at a CAGR of 11.26% between 2023 and 2033, reaching roughly US$ 112.43 billion by 2033, as consumers become increasingly concerned about the extended indications of existing …